Search
Tiapride
go.drugbank.com/drugs/DB13025InvestigationalTiapride is a selective D2 and D3 dopamine receptor blocker in the brain.
Products: TIAPRID-NEURAX 100 MG, TIAPRID-NEURAX 200 MGNilutamide
go.drugbank.com/drugs/DB00665ApprovedInvestigationalNilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer.
Oxabolone cipionate
go.drugbank.com/drugs/DB13185ExperimentalA synthetic anabolic-androgenic (AAS) steroid, it is a derivative of 19-nortestosterone (nandrolone). It is considered as a performance enhancing drug thus is prohibited from use in sports.
XR5944
go.drugbank.com/drugs/DB06364ExperimentalIt has both intercalating and antineoplastic activities.
Cetilistat
go.drugbank.com/drugs/DB06586InvestigationalCetilistat is a novel inhibitor of pancreatic lipase being developed by Alizyme for the treatment of obesity and associated co-morbidities, including type 2 diabetes.
Pagoclone
go.drugbank.com/drugs/DB04903InvestigationalPagoclone is an anxiolytic drug from the cyclopyrrolone family, which is related to other more well known drugs such as the sleeping medication zopiclone. … It is one of a relatively recently developed class of medicines known as the nonbenzodiazepines, which have similar effects to the older benzodiazepine group, but with quite different chemical structures
PH-284
go.drugbank.com/drugs/DB05452ExperimentalPH-284 is under investigation by Pherin and Organon for the treatment of anorexia nervosa, and loss of appetite and cachexia in cancer and AIDS patients. … Vomeropherins are self-administered by the patient with a metered nasal spray, or nasal aerosol device so that they can bind to peripheral chemosensory receptors in the nasal passages.
Mito-4509
go.drugbank.com/drugs/DB05846ExperimentalIt is used to treat Parkinson's Disease, Alzheimer's Disease, Retinal Disorders and other neurologic Disorders.
MKC1106-PP
go.drugbank.com/drugs/DB06030ExperimentalMKC1106-PP is a 3-component investigational vaccine made up of a DNA plasmid (pPRA-PSM) and 2 peptides E-PRA and E-PSM. … MKC1106-PP was under investigation in clinical trial NCT00423254 (Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.).
KP-1461
go.drugbank.com/drugs/DB05644InvestigationalKP-1461 is a potent, non-chain-terminating, mutagenic deoxyribonucleoside analogue. Designated a DNA covert nucleoside, the drug consists of a modified base that incorporates randomly into HIV and pairs with multiple bases.